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Abstract
Background: The Krukenberg tumor represents ovarian metastases associated with gastric
cancer or other gastrointestinal malignancies. Histology shows typical mucus-production and
numerous signet-ring cells. Occasionally Krukenberg tumors have endocrine function and, as a
consequence, some patients demonstrate hirsutism and virilization.
Case presentation: Here we report a case of virilization associated with an extensive gastric
adenocarcinoma and Krukenberg tumor in a premenopausal woman. Virilization occurred three
months after diagnosis of gastric cancer and the ovarian tumors. Palliative chemotherapy was
initiated as primary therapy, but gastric outlet obstruction required a gastrojejunostomy. In
addition, oopherectomy was performed to relieve abdominal tension and to abate hormonal
effects. It is likely that virilization of the patient could have been prevented by earlier oopherectomy
prior to development of hormone production.
Conclusion: Despite the limitation in survival time early oopherectomy should be considered to
prevent the development of virilization even in palliative situations if a Krukenberg tumor is
diagnosed with gastric cancer.
Background
Although incidence and mortality of gastric cancer have
decreased over the last decades, it still remains the fourth
most common cancer and the second leading cause of
cancer-related death worldwide [1,2]. In some cases sec-
ondary tumor from gastric signet-cell adenocarcinoma
appear in the ovaries. It was first described by Krukenberg
in 1896 [3]. Histologically, Krukenberg tumors show dif-
fuse stromal proliferation, mucus-production, and
numerous signet-cells that usually can be found in both
ovaries. In general, a mucus-producing gastric carcinoma
with signet-cells in the stomach is diagnosed as a primary
tumor. McGill et al. showed, that among 233 female
patients with gastric cancer, there is an incidence of Kruke-
nberg tumors of 18.2% in premenopausal women
between 40 to 50 years-old, versus 0% in postmenopausal
women [4]. Diagnosis of Krukenberg tumors represents
advanced malignancy and there is still no effective therapy
for this type of tumor. Therefore, prognosis is poor and
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months [4,5].
Diagnosis is usually accomplished by CT scan or ultra-
sound [5]. The literature reveals several reports of preg-
nant women suffering from Krukenberg tumor in
association with virilization or hirsutism. In these cases,
both mother and infant suffer from the clinical signs of
elevated androgen levels [6,7]. In this context one has to
distinguish hirsutism, which describes an increase in body
hair from virilization, with an additional change to male
body features.
Here we report a case of a 41 years old female patient with
Krukenberg tumor and strong signs of virilization without
pregnancy. The case is of interest because it affected a non-
pregnant patient and virilization occurred only three
months after the initial diagnosis of Krukenberg tumor.
Case presentation
A 41-year-old woman presented to our surgical outpatient
clinic with hypermenorrhea, followed by amenorrhea and
discomfort in the upper abdomen with nausea and eme-
sis. Gastroscopy and histology revealed a poorly differen-
tiated primary gastric mucus-producing adenocarcinoma
with numerous signet-ring cells in the distal corpus and
the antrum. CT scan showed extensive tumor in the lower
abdomen, which appeared to be an ovarian tumor or, as a
differential diagnosis, a Krukenberg tumor (Figure 1).
Endoscopic ultrasound of the tumor resulted in a uT3, N+
stage. Elevated tumor markers like CA 19-9 (817.7 U/ml,
normal range: 0.0–37.0 U/ml), CA 72-4 (92.4 U/ml, nor-
mal range: <4.0 U/ml) and CA 125 (151.4 U/ml, normal
range: <30.2 U/ml) were also present. Virilization was
absent at the time of the initial diagnosis. Surgery was not
initially considered due to the advanced stage of the pri-
mary tumor. Adjuvant chemotherapy was initiated and
the patient received six cycles of epirubicin, cisplatin and
5-fluorouracil, each cycle one week after the ECF regimen
[8].
Side effects of chemotherapy consisted of appetite reduc-
tion, nausea and emesis, and a weight loss of 10 kg within
three months. In addition, the patient developed a
marked increase in body hair covering of her arms, legs,
and face. A notably deeper voice and an androgenized
body feature, with increased muscle strength, were also
observed (Figure 2 and 3). Gynecological examination
revealed no clitoral enlargement. Circulating levels of tes-
tosterone (1.33 μg/l, normal range: <0.62 μg/l), progester-
one (52.29 nmol/l, normal range: 0.64–2.58 nmol/l) and
17-OH-progesterone (14.96 μg/l, normal range:
0.40–1.02 μg/l) were elevated, while other hormones like
estradiol, androstendion, follicle-stimulating hormone,
luteinizing hormone, prolactin and dehydroepiandroster-
one sulfate were in the normal range. Since the patient
experienced increasing episodes of vomiting, a repeat gas-
troscopy was performed. An expanded stomach full of
nutrients, due to gastric outlet obstruction, was found. An
operative intervention to improve the patient's condition
was scheduled. During explorative laparotomy, the two
Krukenberg tumors displacing the small intestine were
found. Tumors and ovaries were removed and intraopera-
tive histology confirmed a Krukenberg tumor from a dif-
fuse gastric carcinoma (Figure 4). In the upper abdomen
an obstructive gastric carcinoma with a widespread perito-
neal carcinomatosis was found. Since complete removal
with R0 resection could not be achieved, a gastrojejunos-
tomy bypassing the stenosis was constructed. The postop-
erative course was without complications and oral feeding
was started successfully on the third day after surgery.
Extensive increase of body hair and muscle mass of the pre-menopausal patientFigure 2
Extensive increase of body hair and muscle mass of 
the premenopausal patient.
CT scan showing two very large ovarian tumors in the lower abdomenFigure 1
CT scan showing two very large ovarian tumors in 
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using 5-fluorouracil (2000 mg/m2) and oxaliplatin (50
mg/m2), with a total of eight cycles in a weekly schedule.
During the chemotherapy tumor markers dropped to 45.2
U/ml (CA 19-9), 13.7 U/ml (CA72-4) and 31.9 U/ml (CA
125). Expectedly, the hormone levels returned to normal
levels. The patient survived for 6 more months before she
died from tumor recurrence, without returning to her nor-
mal phenotype.
Discussion
The Krukenberg tumor is an ovarian metastasis of a pri-
mary tumor derived from abdominal or retroperitoneal
organs [9]. Two-thirds of primary tumors are found in the
stomach. The appendix, colon, small intestine, rectum,
gallbladder and urinary bladder have also been reported
as a site of the original carcinoma [9]. Even intramucosal
gastric cancer may lead to a Krukenberg tumor [10]. Kiy-
okawa et al. reported in an extensive review of 120 cases
that two-thirds of the Krukenberg tumors were diagnosed
at the same time as the primary carcinoma [11]. Our case
parallels this experience, since diagnosis of the gastric
tumor and the Krukenberg tumor were established by the
same CT scan. On the other hand Schoenfeld et al.
reported metachroneous occurrence of a Krukenberg
tumor 8 years after subtotal gastrectomy for adenocarci-
noma [12]. In our case simultanous diagnosis was facili-
tated by clinical symptoms, which hinted to both organs.
These signs were nausea, vomiting and upper abdominal
tension in combination with hypermenorrhea, followed
by amenorrhea. However, only abdominal swelling and
abdominal pain are reported as symptoms of Krukenberg
tumors, whereas abnormal vaginal bleeding and amenor-
rhea occur in only 20% of patients [11]. Most patients
A) Macroscopic view on the resected inhomogeneous tumor form tionsFigure 4
A) Macroscopic view on the resected inhomogene-
ous tumor formations. B) Histology revealed mucus-pro-
ducing glandular structures, small solid nests and signet-ring 
cells surrounded by ovarian stroma.
Androgenized facial featuresFigure 3
Androgenized facial features.Page 3 of 5
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of life and at least two-thirds of the tumors are bilateral
[4,11]. Only a small number of patients have endocrine
manifestations, including virilization, hirsutism, breast
soreness and swelling, postmenopausal vaginal bleeding,
as well as endometrial hyperplasia [11].
It is still unclear why some ovarian metastases lead to
androgenizing hormone production followed by hir-
sutism or even worse, virilization as presented in our case.
From the clinical point of view it is important to recognize
that patients undergoing virilization or hirsutism may suf-
fer from a disturbed body constitution with the serious
consequence of social isolation. Numerous reports of vir-
ilization and hirsutism of mother and infant in associa-
tion with Krukenberg tumors during pregnancy have been
published [6,7,13-20] (Table 1). However, there are no
reports regarding the time course from the diagnosis of a
Krukenberg tumor to the development of virilization or
hirsutism. Furthermore, it is unknown what triggers the
development from hirsutism to virilization, with associ-
ated changes of the female body image.
Histologically the tumor consisted of mucus-producing
glandular structures, small solid nests and numerous sig-
net-ring cells surrounded by partly luteinized ovarian
stroma. In immunohistochemical studies the tumor cells
showed a strong expression of cytokeratin 7 and focal
expression of cytokeratin 20 consistent with the diagnosis
of gastric adenocarcinoma. The neuroendocrine markers
CD56, chromogranin and synaptophysin were negative
ruling out a neuroendocrine subpopulation of the tumor.
In addition, Krukenberg tumors of patients with viriliza-
tion reveal a stromal luteinization, whereas these micro-
scopic findings can be confirmed in only 1 of 4 patients
with hirsutism. Furthermore only 6 of 97 patients lacking
stromal luteinization have been shown to have endocrine
changes. Therefore, it appears that androgenizing hor-
mone production requires development of luteinized
stroma in Krukenberg tumors and it is likely that early
ovarectomy can prevent virilization since spontaneous
regression of virilization is a rare event [11].
Conclusion
In the present case, virilization appeared only three
months after the diagnosis of Krukenberg tumor. The case
suggests that hormone production leading to virilization
requires a minimum period of three months. We therefore
propose that a timely control of androgenizing hormones
should be performed in cases of Krukenberg tumor
derived from gastric cancer. Due to the possibility of rap-
idly developing virilization, surgical resection of sympto-
matic and hormone producing tumors should be offered
to patients even in a palliative setting.
Table 1: Published cases of Krukenberg tumor with virilization. None of them reported time delay between diagnosis of Krukenberg 
tumor and virilization.
Publication Number of reported cases Pregnancy Year of Publication
Interstitial hemorrhage and rupture of a Krukenberg tumor with virilism. 
Wagner et al. (21)
1 No 1950
Krukenberg tumor complicating pregnancy; report of a case with 
androgenic activity. Fox et al. (6)
1 Yes 1965
Virilization coexisting with Krukenberg tumor during pregnancy. Spadoni et 
al. (20)
1 Yes 1965
Gonadotropin-dependent Krukenberg tumor causing virilization during 
pregnancy. Connor et al. (19)
1 Yes 1968
Metabolism of testosterone by virilizing Krukenberg tumor of the ovary. 
Ances at al. (18)
1 No 1968
A case of Krukenberg tumor with virilization aspects. Sani et al. (22) 1 No 1977
Approach to the mechanism of androgen overproduction in a case of 
Krukenbery tumor responsible for virilization during pregnancy. Forest et al. 
(16)
1 Yes 1978
Long-interval masculinizing Krukenberg tumor of the ovary. Schoenfeld et al. 
(12)
1 No 1982
Clinical and ultrastructural findings of an androgenizing Krukenberg tumor 
in pregnancy. Silva et al. (15)
1 Yes 1988
Tubular Krukenberg tumor in pregnancy with virilization. Fung et al. (14) 1 Yes 1991
Krukenberg tumor in pregnancy with virilization. A case report. De Palma 
et al. (13)
1 Yes 1995
Krukenberg tumor during pregnancy with maternal and fetal virilization: a 
difficult diagnosis. A case report. Vauthier-Brouzes et al. (7)
1 Yes 1997
Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases 
with emphasis on their variable pathologic manifestations. Kiyokawa et al. 
(11)
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